- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Biomind Labs Inc: Biomind begins trading on CSE | 2 | Stockwatch | ||
| 11.08. | Canadian Securities Exchange (CSE): Canadian Securities Exchange Welcomes Listing of Biomind Labs Inc. | 383 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Biomind Labs Inc. ("Biomind" or the "Company"). The... ► Artikel lesen | |
| 11.08. | XFRA NEW INSTRUMENTS AVAILABLE ON 11.08.2026 | 259 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.08.2026
Aktien
1 US0906842002 BioStem Technologies... ► Artikel lesen | |
| 07.08. | CSE Bulletin: New Listing - Biomind Labs Inc. (BMND) | 72 | Newsfile | Le 7 août/August 2026
The common shares of Biomind Labs Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the listing date.
Biomind... ► Artikel lesen | |
| 06.08. | Biomind Labs Inc: Biomind Labs to be delisted from Cboe Canada | 1 | Stockwatch | ||
| 06.08. | Biomind Labs Inc.: Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada | 518 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs... ► Artikel lesen | |
| BIOMIND LABS Aktie jetzt für 0€ handeln | |||||
| 03.07. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 02.06. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 21.04. | Biomind Labs Inc: Biomind cheers executive order for psychedelic research | 3 | Stockwatch | ||
| 20.04. | Biomind Labs Inc.: Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States | 418 | ACCESS Newswire | A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20... ► Artikel lesen | |
| 07.03. | Biomind Labs Inc: Biomind Labs under Cboe Canada delisting review | 2 | Stockwatch | ||
| 27.01. | Biomind Labs Inc.: Biomind Labs Announces CAD $2.52 Million Private Placement Financing | 502 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 27.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 27.01.2026 | 228 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 27.01.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 27.01.2026ISIN NameDE000HEL0GB7 LB.HESS.THR.CARRARA04S/25XS2576250448... ► Artikel lesen | |
| 03.12.25 | Biomind Labs Inc.: Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood | 418 | ACCESS Newswire | BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 01.12.25 | XFRA 3XI: WIEDERAUFNAHME/RESUMPTION | 301 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 25.11.25 | Biomind Labs Inc.: Biomind Labs Announces Revocation of Cease Trade Order | 535 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked... ► Artikel lesen | |
| 18.11.25 | Biomind Labs Inc.: Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board | 563 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AAP IMPLANTATE | 1,550 | -3,12 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| CLEARMIND MEDICINE | 1,820 | -0,55 % | Clearmind Medicine Inc.: Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled | Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived... ► Artikel lesen | |
| ALUMIS | 9,470 | 0,00 % | Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) | - LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,680 | 0,00 % | $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| QIAGEN | 37,355 | +0,32 % | QIAGEN profitiert von neuen Spekulationen: QIAGEN Aktie zieht wieder an Übernahmegespräche sorgen für frischen Rückenwind | Die QIAGEN Aktie erholt sich nach zwei schwächeren Handelstagen wieder. Neue Spekulationen über mögliche Übernahmegespräche sorgen am Markt für Kaufinteresse.Übernahmefantasie treibt den Kurs Die QIAGEN... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 41,250 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| BIOAFFINITY TECHNOLOGIES | 6,580 | -0,15 % | bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced... ► Artikel lesen | |
| ERASCA | 16,770 | +0,06 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,160 | 0,00 % | Cantor Fitzgerald reiterates Summit Therapeutics stock rating | ||
| MODERNA | 133,08 | 0,00 % | Krebsimpfstoff: Moderna und Merck melden Erfolg in entscheidender Studie | Eine experimentelle Therapie könnte den Weg für eine neue Klasse personalisierter Krebsmedizin ebnen. Ob daraus ein großes Geschäft wird, hängt von der Wirksamkeit bei weiteren Tumorarten sowie von... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 353,24 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 25,570 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval - - Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 135,07 | -0,01 % | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,420 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| IMMUNOVANT | 39,920 | +0,05 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen |
Das Unternehmen BIOMIND LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,292 Euro und damit -17,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMIND LABS INC finden Sie auf Wallstreet Online.